Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
5 ASX shares to buy at deep discounts today
Coronavirus News
Is it time to buy Coca Cola Amatil shares?
Share Market News
The ASX 200 was very volatile again this week
Resources Shares
Why these ASX miners could outperform over the next two months
Capital Raising
How will COVID-19 hit Webjet perform when it returns to the market?
Share Market News
Brokers name 3 ASX 200 shares to buy
Share Market News
ASX tech share latest to dump its dividend and guidance
Coronavirus News
Why next month may be the right time to buy the bear market
⏸️ TMF AMP
ASX 200 lunch update: Brickworks & NAB higher, Cochlear returns
Healthcare Shares
Cochlear share price edges lower on successful completion of capital raise
Cheap Shares
Macquarie's best ASX 200 buys for the "inevitable recovery"
⏸️ TMF AMP
ASX 200 finishes 5.5% higher
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
